

Multifunctional gene delivery vectors containing different liver-targeting fragments for specifically transfecting hepatocellular carcinoma (HCC) cells

Qin Cheng^{a, b, 1}, Taoran Wang^{a, 1}, Jing Zhang^{a, b}, Long Tian^{a, c}, Chunlan Zeng^a, Zhao Meng^{a, *}, Changhao Zhang^{b, *}, Qingbin Meng^{a, c, *}

^a State Key laboratory of Toxicology and Medical Countermeasures, Beijing institute of Pharmacology and Toxicology, Beijing, 100850, China

^b Key laboratory of Natural Medicines of the Changbai Mountain, Ministry of education, College of Pharmacy, Yanbian University, Yanji, 133002, China

^c Key Laboratory of Structure-Based Drug Design and Discovery of the Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China

¹ These authors contributed to the work equally.

* Corresponding author.

Author Email Address:

Zhao Meng: mengzhao900817@163.com

Changhao Zhang: zhangch@ybu.edu.cn

Qingbin Meng: nankaimqb@sina.com

Table S1. Sequences and molecular weights (MWs) of peptides.

Figure S1. RP-HPLC of peptide vectors.

Figure S2. MALDI-TOF-MS or ESI-MS of peptide vectors.

Figure S3. Agarose gel electrophoresis assays of peptide vectors at different N/P ratios.

Figure S4. TEM images of peptide/DNA complexes at the N/P ratio of 10. The scale bar represents 200 nm.

Table S2. The concentrations of peptide/DNA complexes in the cytotoxicity analysis.

Figure S5. Flow cytometric analysis of cellular uptake mechanisms of H-02/DNA (A) and H-09/DNA (B) complexes in HepG2 cells using specific endocytosis inhibitors. The DNA was labeled with YOYO-1.


Table S3. The mean intensity of the green fluorescence in HepG2 and LO2 cells measured by ImageJ in CLSM analysis.

Table S4. The CLR of DAPI and YOYO-1 in live-cell imaging experiments.


Table S1. Sequences and molecular weights of peptides.

| Compounds | Peptide sequences | MWs | |
|-----------|---|------------|----------|
| | | Calculated | Measured |
| H-01 | K(C ₁₈)-(LLHH) ₃ -R ₉ | 3359.38 | 3361.07 |
| H-02 | KVGGNY-K(C ₁₈)-(LLHH) ₃ -R ₉ | 3937.82 | 3938.32 |
| H-03 | KVGGNNYNYRLF-K(C ₁₈)-(LLHH) ₃ -R ₉ | 4907.94 | 4909.86 |
| H-04 | NGVEGFN-K(C ₁₈)-(LLHH) ₃ -R ₉ | 4036.86 | 4037.77 |
| H-05 | HAIYPRH-K(C ₁₈)-(LLHH) ₃ -R ₉ | 4194.12 | 4191.07 |
| H-06 | AHLHNRS-K(C ₁₈)-(LLHH) ₃ -R ₉ | 4135.00 | 4132.08 |
| H-07 | DYEMHLWWGTEL-K(C ₁₈)-(LLHH) ₃ -R ₉ | 4880.84 | 4877.56 |
| H-08 | THVSPNQGGLPS-K(C ₁₈)-(LLHH) ₃ -R ₉ | 4494.38 | 4491.35 |
| H-09 | KSLSRHDHIHHH-K(C ₁₈)-(LLHH) ₃ -R ₉ | 4804.75 | 4803.59 |
| H-10 | SFSIIHTPILPL-K(C ₁₈)-(LLHH) ₃ -R ₉ | 4638.72 | 4635.55 |
| H-11 | GNY-K(C ₁₈)-(LLHH) ₃ -R ₉ | 3653.46 | 3652.47 |
| H-12 | GVKYNG-K(C ₁₈)-(LLHH) ₃ -R ₉ | 3937.82 | 3934.97 |
| H-13 | DHIHHH-K(C ₁₈)-(LLHH) ₃ -R ₉ | 4095.95 | 4095.23 |
| H-14 | HKHDSHLISHRH-K(C ₁₈)-(LLHH) ₃ -R ₉ | 4804.75 | 4801.88 |
| H-15 | KVGGNY | 635.72 | 637.05 |
| H-16 | KSLSRHDHIHHH | 1502.65 | 1502.47 |
| H-17 | K(C ₁₈)-C(Cy5.5)-(LLHH) ₃ -R ₉ | 4127.11 | 4131.12 |
| H-18 | KSLSRHDHIHHH-K(C ₁₈)-C(Cy5.5)-(LLHH) ₃ -R ₉ | 5612.74 | 5617.75 |


H-01





H-02




H-03




H-04




H-06






07

H-08







H-




09

H-10






H-




14


H-15



16



H-17



H-18






Figure S1. RP-HPLC of peptide vectors.


H-01




H-02




H-03




H-04




H-05




H-06




H-07




H-08




H-09




H-10





H-11




H-12




H-13




H-15



H-16



H-17






Figure S2. MALDI-TOF-MS or ESI-MS of peptide vectors.




Figure S3. Agarose gel electrophoresis assays of peptide vectors at different N/P ratios.




Figure S4. TEM images of peptide/DNA complexes at the N/P ratio of 10. The scale bar represents 200 nm.

Table S2. The concentrations of peptide/DNA complexes in the cytotoxicity analysis

| Compounds | Concentrations (μM) | | | | |
|-----------|----------------------------------|------|------|------|------|
| | 4 | 6 | 8 | 10 | 12 |
| H-01 | 1.37 | 2.05 | 2.74 | 3.42 | 4.11 |
| H-02 | 1.23 | 1.85 | 2.46 | 3.08 | 3.70 |
| H-03 | 1.12 | 1.68 | 2.24 | 2.80 | 3.36 |
| H-04 | 1.54 | 2.31 | 3.08 | 3.85 | 4.62 |
| H-05 | 1.23 | 1.85 | 2.46 | 3.08 | 3.85 |
| H-06 | 1.23 | 1.85 | 2.46 | 3.08 | 3.85 |
| H-07 | 2.05 | 3.08 | 4.11 | 5.13 | 6.16 |
| H-08 | 1.37 | 2.05 | 2.74 | 3.42 | 4.11 |
| H-09 | 1.23 | 1.85 | 2.46 | 3.08 | 3.70 |
| H-10 | 1.37 | 2.05 | 2.74 | 3.42 | 4.11 |




Figure S5. Flow cytometric analysis of cellular uptake mechanisms of H-02/DNA (A) and H-09/DNA (B) complexes in HepG2 cells using specific endocytosis inhibitors. The DNA was labeled with YOYO-1.

Table S3. The mean intensity of the green fluorescence in HepG2 and LO2 cells measured by ImageJ in CLSM analysis

| Compounds | Mean intensity | |
|-----------|----------------|--------|
| | HepG2 | LO2 |
| H-01 | 90.41 | 117.31 |
| H-02 | 198.51 | 139.97 |
| H-03 | 53.21 | 57.78 |
| H-04 | 189.18 | 158.10 |
| H-05 | 132.09 | 83.77 |
| H-06 | 86.88 | 88.12 |
| H-07 | 198.64 | 85.06 |
| H-08 | 46.99 | 83.32 |
| H-09 | 203.89 | 122.41 |
| H-10 | 113.66 | 61.18 |
| Lipo 2000 | 53.76 | 90.87 |

Table S4. The CLR of DAPI and YOYO-1 in live-cell imaging experiments

| Time (min) | CLR (%) | | | |
|------------|---------|-------|-------|-----------|
| | H-01 | H-02 | H-09 | Lipo 2000 |
| 5 | 7.33 | 10.27 | 16.64 | - |
| 15 | 18.44 | 20.71 | 20.72 | 10.40 |
| 60 | 21.99 | 47.22 | 29.94 | 26.27 |
| 120 | 22.57 | 49.11 | 60.56 | 48.15 |
| 240 | - | - | - | 83.64 |